autologous admscs  (Bioheart Inc)

Journal: Journal of Orthopaedic Translation

Article Title: Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: Systematic review and meta-analysis of randomized controlled trials

doi: 10.1016/j.jot.2024.07.012

Figure Lengend Snippet: Main characteristics of the included clinical trials.

Article Snippet: 16 , Lu 2020 [ ] , China , N = 53 Mean age between 55.03 (9.19) and 59.64 (5.97) (p = 0.0375) years KL grade I-III KOA , Autologous ADMSC (5.0 × 10 7 cells) N = 26 , VS N = 26 , Adverse events Serious adverse events VAS WOMAC SF-36 MRI cartilage volume , Up to 12 months , Cellular Biomedicine Group Ltd. Protocol registration reported (NCT02162693).

Techniques: Comparison, Control

Journal: PLOS ONE

Article Title: Safety and efficacy of mesenchymal stem cells therapy in the treatment of rheumatoid arthritis disease: A systematic review and meta-analysis of clinical trials

doi: 10.1371/journal.pone.0284828

Figure Lengend Snippet: Summary of active RA clinical trials with MSC therapy that included a control group.

Article Snippet: NCT04170426 , 2019 , United States , Phase 1 Phase 2 , Active, Not yet recruiting , Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis , Refractory Rheumatoid Arthritis , Biological: autologous adipose derived stem cells , Placebo , Safety profile , Celltex Therapeutics Corporation , December 2025.

Techniques: Derivative Assay

Journal: Cytotechnology

Article Title: Taming of Covid-19: potential and emerging application of mesenchymal stem cells

doi: 10.1007/s10616-021-00461-8

Figure Lengend Snippet: Summary of some of the registered clinical trials in ClinicalTrials.gov regarding the application of MSCs to treat COVID-19

Article Snippet: 30 , NCT04428801 , June 11, 2020 200 participant s , Not yet recruiting , Autologous Adipose- derived Stem Cells (AdMSCs) for COVID-19 , COVID-19 , Biological: autologous adipose- derived stem cells Other Name: Celltex- AdMSCs , Intervention al , Phase 2 , Allocation: Randomized Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Treatment Treatment Double (Participant, Outcomes Assessor) , Celltex Therapeutics Corporation.

Techniques: Infection, Derivative Assay, Northern Blot, Ex Vivo

Journal: Biomedicine & Pharmacotherapy

Article Title: Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review

doi: 10.1016/j.biopha.2021.111300

Figure Lengend Snippet: List of registered stem cell therapy based clinical trials for COVID-19.

Article Snippet: Guillory et al. 2020 [ ] , Phase 2 multi-center, double-blind, randomized, placebo-control clinical trial , Not yet recruiting , 200 (18 years and older) , Autologous Adipose Tissue-Derived MSCs (Celltex-AdMSCs) , Phase 2 Placebo group , Primary Outcome: Safety and Tolerability Incidence of COVID-19 in study and control group.

Techniques: Derivative Assay, Transplantation Assay, Infection, Ex Vivo, Injection

Journal: Stem Cell Research & Therapy

Article Title: Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients

doi: 10.1186/s13287-020-01963-6

Figure Lengend Snippet: Ongoing clinical trials using MSCs and MSC-derived exosomes to treat COVID-19 patients

Article Snippet: NCT04428801 , RCT, double* masking , 2 , Autologous AT-MSCs (Celltex-AdMSCs) , 200 million every 3 days (3 doses), IV , 200 , Placebo (not defined) , USA , Not yet recruiting.

Techniques: Clinical Proteomics, Control, Saline, Aerosol, Derivative Assay